Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec to refine focus of research efforts

Biogen Idec to refine focus of research efforts

5th November 2010

Biogen Idec has announced that it will be altering the focus of its research and development efforts as part of a wider efficiency improvement programme.

Moving forward, the company is to focus exclusively on the area of neurology and will be spinning out or out-licensing its oncology assets, as well as exiting the cardiovascular health market.

This new strategy is being put into place effective immediately, with Biogen Idec revealing in a separate announcement that it is ending its collaboration with Cardiokine on the hyponatremia treatment lixivaptan.

The firm expressed confidence that this new approach will give it a greater focus on its primary area of expertise, allowing it to become a global leader in addressing conditions such as multiple sclerosis.

Its new efficiency programme will also allow Biogen Idec to make cost savings of around $300 million (185.2 million pounds) annually.

Dr George Scangos, Biogen Idec's chief executive officer, said: "As a result of these actions, Biogen Idec will be leaner, more nimble and more decisive."ADNFCR-8000103-ID-800219252-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.